MX2018005569A - Vacunas contra el virus de la hepatitis b. - Google Patents

Vacunas contra el virus de la hepatitis b.

Info

Publication number
MX2018005569A
MX2018005569A MX2018005569A MX2018005569A MX2018005569A MX 2018005569 A MX2018005569 A MX 2018005569A MX 2018005569 A MX2018005569 A MX 2018005569A MX 2018005569 A MX2018005569 A MX 2018005569A MX 2018005569 A MX2018005569 A MX 2018005569A
Authority
MX
Mexico
Prior art keywords
virus
hepatitis
vaccines against
against hepatitis
vaccines
Prior art date
Application number
MX2018005569A
Other languages
English (en)
Inventor
Monath Thomas
Cohen Katherine
Baumgartl-Strasser Vera
Original Assignee
Hookipa Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Ag filed Critical Hookipa Biotech Ag
Publication of MX2018005569A publication Critical patent/MX2018005569A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

La presente invención proporciona inmunoterapias para infecciones por virus de la hepatitis B. Se proporcionan en la presente vectores de arenavirus genéticamente modificados adecuados como vacunas para la prevención y el tratamiento de infecciones por virus de la hepatitis B. También se proporcionan en la presente composiciones farmacéuticas y métodos para el tratamiento de infecciones por virus de la hepatitis B. Específicamente, aquí se proporcionan composiciones farmacéuticas, vacunas y métodos para tratar la infección por virus de la hepatitis B.
MX2018005569A 2015-11-04 2016-11-03 Vacunas contra el virus de la hepatitis b. MX2018005569A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250639P 2015-11-04 2015-11-04
PCT/EP2016/076591 WO2017076988A1 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Publications (1)

Publication Number Publication Date
MX2018005569A true MX2018005569A (es) 2018-12-19

Family

ID=57249796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005569A MX2018005569A (es) 2015-11-04 2016-11-03 Vacunas contra el virus de la hepatitis b.

Country Status (22)

Country Link
US (2) US11214598B2 (es)
EP (2) EP3371316B1 (es)
JP (3) JP6914950B2 (es)
KR (1) KR20180082485A (es)
CN (2) CN115948467A (es)
AU (2) AU2016348675B2 (es)
BR (1) BR112018009032A8 (es)
CA (1) CA3003557A1 (es)
DK (1) DK3371316T3 (es)
ES (1) ES2934698T3 (es)
FI (1) FI3371316T3 (es)
HK (1) HK1255847A1 (es)
HR (1) HRP20221474T1 (es)
HU (1) HUE060648T2 (es)
IL (1) IL259077A (es)
LT (1) LT3371316T (es)
MX (1) MX2018005569A (es)
PL (1) PL3371316T3 (es)
PT (1) PT3371316T (es)
SG (1) SG11201803474UA (es)
SI (1) SI3371316T1 (es)
WO (1) WO2017076988A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5642556B2 (ja) 2007-12-27 2014-12-17 ユニヴァーシテト チューリッヒ 複製欠損アレナウイルスベクター
CN105980570B (zh) 2013-12-03 2022-06-07 霍欧奇帕生物科技有限公司 Cmv疫苗
AU2015345080B2 (en) * 2014-11-13 2022-01-27 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
CN107921117B (zh) 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
LT3371316T (lt) 2015-11-04 2022-11-25 Hookipa Biotech Gmbh Vakcinos nuo hepatito b viruso
AU2016352572B2 (en) 2015-11-12 2023-10-19 Hookipa Biotech Gmbh Arenavirus particles as cancer vaccines
AU2017342536A1 (en) 2016-10-14 2019-05-02 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome
JP2022010187A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
JP2022010188A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2020255023A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
CA3143680A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
CN114245807A (zh) 2019-06-25 2022-03-25 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
AU2020412875A1 (en) 2019-12-24 2022-06-23 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
KR102375703B1 (ko) 2020-07-28 2022-03-17 경북대학교 산학협력단 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템
CA3213083A1 (en) 2021-03-23 2022-09-29 Igor MATUSHANSKY Arenaviruses used in treatments of prostate cancer
WO2022226242A1 (en) * 2021-04-21 2022-10-27 La Jolla Institute For Immunology Engineered arenavirus glycoprotein compositions, methods and use thereof
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc DIACYLGLYERCOL KINASE MODULATING COMPOUNDS

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH1084967A (ja) 1996-09-19 1998-04-07 Fujirebio Inc Ｂ型肝炎のｅ抗原
BR9915942A (pt) * 1998-12-04 2001-08-21 Biogen Inc Patìculas de antìgeno de núcleo de hbv com componentes imunogênicos múltiplos ligados através de ligantes de peptìdeo
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
WO2006125983A1 (en) * 2005-05-23 2006-11-30 Oxxon Therapeutics Ltd Compositions for inducing an immune response against hepatitis b
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
NZ704295A (en) * 2006-12-27 2016-06-24 Harvard College Compositions and methods for the treatment of infections and tumors
JP5642556B2 (ja) 2007-12-27 2014-12-17 ユニヴァーシテト チューリッヒ 複製欠損アレナウイルスベクター
MX2012001592A (es) * 2009-08-07 2012-05-22 Transgene Sa Composicion para el tratamiento de la infección del virus de la hepatitis b.
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
CN104159607A (zh) 2012-01-24 2014-11-19 桑福德研究院/南达科他大学 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
CN105980570B (zh) 2013-12-03 2022-06-07 霍欧奇帕生物科技有限公司 Cmv疫苗
US10342861B2 (en) 2014-05-27 2019-07-09 University Of Rochester Arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
JP6875274B6 (ja) 2014-09-22 2021-06-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ピチンデウイルスのリバースジェネティクス系及び使用方法
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
AU2015345080B2 (en) 2014-11-13 2022-01-27 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
CN107921117B (zh) 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
EP3365005A1 (en) 2015-10-23 2018-08-29 Institut Pasteur Recombinant mopeia virus and vaccine platform
LT3371316T (lt) 2015-11-04 2022-11-25 Hookipa Biotech Gmbh Vakcinos nuo hepatito b viruso
AU2016352572B2 (en) 2015-11-12 2023-10-19 Hookipa Biotech Gmbh Arenavirus particles as cancer vaccines
WO2017190074A1 (en) 2016-04-28 2017-11-02 The University Of Chicago Lymphangiogenesis for therapeutic immunomodulation
US20190135875A1 (en) 2016-05-18 2019-05-09 Hookipa Biotech Gmbh Tri-segmented pichinde viruses as vaccine vectors
JP2019533690A (ja) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
CA3058539A1 (en) 2017-04-07 2018-10-11 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
JP2018536433A (ja) 2018-12-13
CA3003557A1 (en) 2017-05-11
JP2024010027A (ja) 2024-01-23
CN108779472A (zh) 2018-11-09
FI3371316T3 (fi) 2023-01-13
BR112018009032A8 (pt) 2019-02-26
CN108779472B (zh) 2022-09-09
JP2021182922A (ja) 2021-12-02
SI3371316T1 (sl) 2023-02-28
IL259077A (en) 2018-06-28
SG11201803474UA (en) 2018-05-30
US20180319845A1 (en) 2018-11-08
JP6914950B2 (ja) 2021-08-11
AU2016348675B2 (en) 2022-11-17
NZ741950A (en) 2023-10-27
PT3371316T (pt) 2022-11-17
BR112018009032A2 (pt) 2018-11-06
US11214598B2 (en) 2022-01-04
KR20180082485A (ko) 2018-07-18
AU2016348675A1 (en) 2018-05-17
AU2023200108A1 (en) 2023-02-16
DK3371316T3 (da) 2023-01-23
HK1255847A1 (zh) 2019-08-30
US20220073568A1 (en) 2022-03-10
EP3371316A1 (en) 2018-09-12
WO2017076988A1 (en) 2017-05-11
EP4177348A1 (en) 2023-05-10
CN115948467A (zh) 2023-04-11
LT3371316T (lt) 2022-11-25
HRP20221474T1 (hr) 2023-01-06
HUE060648T2 (hu) 2023-04-28
PL3371316T3 (pl) 2023-02-13
EP3371316B1 (en) 2022-10-19
ES2934698T3 (es) 2023-02-24

Similar Documents

Publication Publication Date Title
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
HK1251219A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的6，7-二氫吡啶並[2，1-a]酞嗪-2-酮類化合物
PH12018500573A1 (en) Hepatitis b core protein modulators
CY1124288T1 (el) Cmv εμβολια
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
PH12016501379A1 (en) Azepane derivatives and methods of treating hepatitis b infections
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
MX2017005252A (es) Metodos para la preparacion de ribosidos.
EP3505620A4 (en) 2D ORGANOID FOR INFECTIONS AND GROWTH OF HUMAN DIARRHOEVIRUS AND USE OF THE TWO-DIMENSIONAL ORGANOID
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в